top of page

Occam Places Ryan Kruger as CSO of Anagenex

Ryan Kruger joins Anagenex, a cutting-edge platform company marrying Machine Learning with DNA-encoded libraries to discover the next generation of small molecule medicines at scale. Anagenex, a Lux investment, recently closed a $30 million Series A financing round led by Catalio Capital Management.

Kruger joins Anagenex from Foghorn Therapeutics, a clinical-stage biotech, where he served as Vice President, Head of Biology overseeing all aspects of discovery biology, translational medicine, and early clinical development. Previously, Ryan spent fifteen years at GSK, most recently as Vice President, Head of the Cancer Epigenetics Research Unit, Oncology R&D where he shepherded six novel small molecule therapies from discovery to clinical development.

In Kruger, Anagenx captures a creative drug hunter with a demonstrated record of success assembling robust pipelines of programs and pushing them forward into the clinic in both large and small company settings. As CSO, Ryan will partner closely with Joe Franklin, SVP & Head of Early Discovery, whom Occam also placed at Anagenex in 2020. Finally, Kruger will doubtlessly benefit from wisdom at the Board level in Tito Serafini whom Occam also placed in 2020.

bottom of page